FGFR2 and ductal breast carcinoma in situ: In this study, we found that FGFR2 knock-down in HB2 cells, a nontumorigenic mammary epithelial cell line in vitro [25] and in vivo model of Ductal Carcinoma In Situ (DCIS) [26], affected morphology of the colonies in three-dimensional (3D) cultures in vitro and downregulated expression of integrins α2, α5 and β1.